Stryker Buys Target Neurovascular Biz From Boston Scientific For $1.5 Billion
This article was originally published in The Gray Sheet
Executive Summary
Stryker will enter the neurovascular market and become segment leader through the $1.5 billion purchase of Target Therapeutics from Boston Scientific, the firms announced Oct. 28.